GLP-1 and Anesthesia: What the Surgery Guidelines Actually Say

In June 2023, anesthesiologists were told to do one thing with Ozempic before surgery: stop it. By October 2024, the same specialty told them to mostly keep patients on it. That whiplash is not a sign of confusion. It is a sign that the data finally caught up with the panic, and the result is one of the more sensible course corrections in recent perioperative medicine.

If you take a GLP-1 medication and you have a procedure coming up, here is what actually changed and what it means for the morning you show up fasting.

What do the current GLP-1 and anesthesia surgery guidelines actually say?

The 2024 multisociety guidance, endorsed by the American Society of Anesthesiologists and four other organizations, advises that most patients can continue their GLP-1 receptor agonist before elective surgery. Decisions should be risk-based and shared between patient and care team, rather than a blanket order to stop the drug a week out.

This replaced the more cautious stance the ASA issued in June 2023, which told patients to hold daily-dose GLP-1 drugs on the day of surgery and weekly-dose versions one week before (ASA consensus guidance, 2023). The newer document, published in Clinical Gastroenterology and Hepatology and co-authored with the American Gastroenterological Association, the American Society for Metabolic and Bariatric Surgery, the International Society of Perioperative Care of Patients with Obesity, and the Society of American Gastrointestinal and Endoscopic Surgeons, moved the field toward individualized assessment (Multisociety guidance, 2024).

The practical shift is from a calendar rule to a clinical judgment. The 2023 version was easy to follow and easy to get wrong, because a single date on a calendar cannot capture whether a given patient’s stomach is actually empty on the morning of surgery. The 2024 version asks a harder but better question: is this particular person, on this particular drug and dose, at meaningful risk today? That is more work for the care team and it puts more weight on what you tell them, which is exactly why understanding the reasoning matters.

Why were doctors worried about GLP-1 drugs and anesthesia in the first place?

The whole concern comes down to one mechanism: GLP-1 receptor agonists slow gastric emptying. That is part of how they make you feel full and lose weight. It is also exactly the wrong property to have when an anesthesiologist is about to render you unconscious and your airway reflexes disappear.

When you are put under general anesthesia, the body loses its protective gag and cough reflexes. If the stomach still holds food hours after you stopped eating, that retained material can come up and go down the wrong way into the lungs. This is pulmonary aspiration, and it can cause a serious chemical pneumonitis. The standard fasting rules (no solids for six to eight hours, clear liquids up to two) assume a normally emptying stomach. GLP-1 drugs break that assumption.

The endoscopy data made the risk visible. In a retrospective case-control analysis of semaglutide users undergoing upper endoscopy, 12.5 percent of patients on the drug had retained gastric contents versus 1.3 percent of matched controls, close to a tenfold difference, and the signal was even stronger among people taking it for weight loss, near 23 percent (Silveira et al., retrospective analysis). Six endoscopies in that cohort had to be aborted because of how much food was still sitting in the stomach. The Anesthesia Patient Safety Foundation also published case reports of patients with large amounts of solid food found in the stomach despite proper fasting (APSF case series).

How do the different GLP-1 drugs differ before surgery?

Not all GLP-1 drugs behave the same way around a procedure, and the difference comes down to how long they linger in your system. This is why the old one-size rule fit poorly.

The weekly injectables, semaglutide (Ozempic, Wegovy) and dulaglutide (Trulicity), along with the dual agonist tirzepatide (Mounjaro, Zepbound), are built to last. Semaglutide has a half-life of about a week, which is precisely why a single seven-day pause never fully removed the gastric-emptying effect the way the 2023 rule implied. Tirzepatide clears somewhat faster but is still a multi-day drug. The daily drugs are a different story: liraglutide (Victoza, Saxenda) has a half-life measured in hours, and oral semaglutide (Rybelsus) is taken every day. Shorter-acting drugs wash out of the equation faster, which is part of why the daily versions were treated more leniently even under the older guidance.

The point is not to memorize half-lives. It is to understand why your anesthesiologist needs to know the exact drug and the exact schedule, not just the phrase “a weight-loss shot.” A weekly drug at a high maintenance dose and a daily pill are simply not the same risk on the morning of surgery, and the plan should reflect which one is in your body.

If the stomach holds food, why did the guidelines loosen instead of tighten?

Here is the nuance that the 2023 headlines missed. A full stomach on a scope is alarming. An actual aspiration event in the operating room turned out to be rare.

When researchers looked past gastric contents to real clinical harm, the aspiration numbers stayed low. A systematic review and meta-analysis of more than 200,000 patients undergoing elective upper endoscopy found pulmonary aspiration in about 0.16 percent of GLP-1 users versus 0.12 percent of non-users, a difference that was not statistically significant (odds ratio 1.23). For context, the background rate of aspiration during endoscopy in the general population sits around 4.6 events per 10,000 (systematic review and meta-analysis, 2025). In other words, retained food went up several-fold, but the rate of someone actually aspirating did not climb the way the early fear suggested.

The 2023 advice to hold weekly drugs for a full week also created its own problems. Many of these medications have long half-lives, so a one-week pause does not fully clear the gastric-emptying effect anyway. Meanwhile, holding the drug can swing blood sugar in people with diabetes and disrupt a treatment that is doing real metabolic work. The 2024 panel weighed those costs against a low absolute aspiration rate and concluded that stopping everyone was the wrong trade.

Who still needs to hold their GLP-1 before surgery?

The 2024 guidance is risk-based, not permissive across the board. It flags specific factors that push a patient into the higher-risk category for delayed gastric emptying:

• Dose-escalation phase. The early weeks of titrating up to a higher dose carry more gastric-emptying effect than the steady maintenance phase.
• Higher doses and weekly formulations. GI side effects are more common with weekly compounds than daily ones.
• Active GI symptoms. Nausea, vomiting, abdominal pain, bloating, or dyspepsia on the day of the procedure all suggest the stomach is not emptying normally.
• Conditions that already slow the gut. Gastroparesis, bowel dysmotility, and Parkinson disease compound the effect.

A patient in steady maintenance with no GI symptoms and no other risk factors is generally cleared to continue. A patient mid-escalation, on a high weekly dose, feeling queasy that morning, is a different conversation.

The type of anesthesia matters too. The aspiration concern is centered on general anesthesia and deep sedation, where your airway reflexes are switched off. A procedure done under a regional or spinal block, or light sedation where you keep your own reflexes, carries a different and generally lower aspiration risk. That is one more variable the anesthesiologist folds in, and it is another reason the decision cannot be reduced to a rule you apply at home.

What about emergency surgery, colonoscopy, and bariatric surgery?

Elective surgery is where shared decision-making has room to breathe. Emergency surgery is not. If you need an urgent operation, there is no time to optimize an empty stomach, so the anesthesiologist simply assumes you have a full one and manages the airway accordingly, often with a rapid sequence induction. Being on a GLP-1 reinforces that assumption rather than changing the plan.

Endoscopy and colonoscopy deserve their own mention because they are so common in this group. Upper endoscopy is exactly where the retained-food signal first showed up, which is why gastroenterologists are attentive to GLP-1 use before a scope. Colonoscopy is a slightly different case, because the bowel prep already puts you on clear liquids for many hours beforehand, and that extended liquid-only window helps empty the upper gut as well. It does not erase the concern, but it is part of why the perioperative conversation looks a little different for a colonoscopy than for a solid-food morning before surgery.

Bariatric and metabolic surgery is its own world, because so many of these patients are on a GLP-1 for the same reason they are having the operation. Surgeons and anesthesiologists in that setting are highly familiar with the drugs and build the perioperative plan around them as a matter of routine. If your procedure is weight-related, assume the team has seen this many times, and still tell them the specifics.

If your GLP-1 is paused, what happens to your blood sugar?

For someone taking a GLP-1 purely for weight, a short pause is mostly about the stomach. For someone with type 2 diabetes, pausing the drug removes part of their glucose control, and blood sugar can drift up in the days without it. This is not a reason to refuse a hold if the team recommends one. It is a reason to have a plan for the gap.

In practice, that means your prescriber or the hospital team may bridge the pause with other glucose management, and your numbers may need closer watching around the procedure than usual. It also means the decision to hold is genuinely a trade-off, airway safety on one side, glucose control on the other, which is exactly the balancing act the 2024 guidance hands to the care team rather than to a fixed rule. The takeaway for you is simple: if you have diabetes, make sure the people managing your surgery and the person managing your diabetes are talking to each other.

What happens at the hospital on the day of your procedure?

The care team assesses symptoms on arrival. When there is concern that food may still be in the stomach, the guidance offers two practical tools.

First, a preoperative clear liquid diet for at least 24 hours can reduce residual stomach contents for higher-risk patients, an approach borrowed from how anesthesiologists already prep patients with known gastroparesis. Second, point-of-care gastric ultrasound can be used to look directly at whether the stomach is full or empty, though the guidance acknowledges this is limited by equipment, training, and operator variability.

If concern remains or ultrasound confirms retained contents, the anesthesiologist can use a rapid sequence induction to secure the airway quickly and lower aspiration risk, or in some cases delay the procedure. This is shared decision-making in practice: the team weighs your metabolic need for the drug against the airway risk and picks the safest path together.

After the procedure, when do you restart the drug?

Coming off a GLP-1 for a few days does not undo months of progress, so there is no need to panic about a short interruption. The usual approach is to resume the medication once you are eating and drinking normally again and your gut is behaving, rather than restarting it while you are still nauseated or not tolerating food. If you were mid-titration before surgery, your prescriber may have you step back onto the ladder rather than jumping straight to your previous dose, since tolerance can slip during a break. As with everything else here, the specifics belong to the clinician who prescribed it, and the restart is worth confirming with them rather than guessing.

Know your metabolic baseline before an elective procedure

An elective operation is one of the few moments when people actually pause to take stock of their health, and it is a good moment to do it properly. Most people on a GLP-1 are on it because their metabolism needed help, and the same numbers that matter for that also matter for how well you tolerate surgery and recovery. Blood sugar control, measured by HbA1c and fasting glucose, influences healing and infection risk. A basic metabolic and blood-count picture tells the team where you stand going in. Knowing these numbers before you show up fasting is simply better than finding out on the operating schedule.

This is less about the drug and more about walking into a procedure with your eyes open. If it has been a while since anyone looked at your full metabolic panel, the run-up to an elective surgery is a sensible time to fix that.

What should you, the patient, do before surgery?

Do not stop or change a prescription medication on your own based on a blog post. The single most useful action is to tell every team involved, surgeon, anesthesiologist, and prescriber, that you take a GLP-1 drug, which one, what dose, and how recently you started or increased it. That information is what lets them place you correctly on the risk spectrum.

A short, concrete checklist for the pre-op call or appointment:

• Name the exact drug and dose, and say whether it is weekly or daily.
• Say when your last dose was, and whether you have increased the dose recently.
• Report any current GI symptoms, nausea, bloating, reflux, or a sense that food sits heavily.
• Mention if you have diabetes and who manages it, so the glucose plan and the surgery plan line up.
• Ask directly what they want you to do about the drug and about eating and drinking, and get it in writing.

If you want background on this drug class and how these peptides behave in the body, our overview of peptides explained is a useful primer, and our guide to GLP-1 side effects covers the gastrointestinal symptoms that matter most here.

A note on compounded and grey-market GLP-1 products

Worth saying plainly: the published guidance was written around FDA-approved GLP-1 medications such as semaglutide, liraglutide, and tirzepatide. Compounded, research-grade, or grey-market versions sold outside the regulated supply chain do not come with verified dosing or purity, which makes risk assessment harder, not easier. If you are using any non-prescription version, disclose it anyway. Your anesthesiologist cannot account for a drug they do not know is in your system.

This is also a good argument for getting these drugs through a real clinician in the first place. A prescriber who knows your dose, your titration history, and your other conditions is exactly the person an anesthesiologist wants to coordinate with before a procedure. A vial bought online with no paper trail leaves everyone guessing at the moment guessing is most dangerous.

Frequently asked questions

Do I have to stop Ozempic before surgery?

Not automatically. Under the 2024 multisociety guidance, most patients in stable maintenance dosing without GI symptoms can continue. Patients in the dose-escalation phase, on high weekly doses, or with nausea and bloating may be asked to hold the dose or follow a clear liquid diet. Confirm with your own care team.

How long before surgery should a GLP-1 be held if my doctor decides to hold it?

The older 2023 ASA advice suggested holding daily formulations the day of surgery and weekly formulations one week before. The 2024 guidance favors an individualized approach over a fixed timeline, sometimes using a 24-hour clear liquid diet instead of stopping the drug entirely.

Is aspiration under anesthesia common with GLP-1 drugs?

Retained food in the stomach is clearly more common, on the order of a tenfold increase on endoscopy in one semaglutide study. Actual aspiration events remain rare. A large meta-analysis found about 0.16 percent in GLP-1 users versus 0.12 percent in non-users, not a statistically significant difference, against a general-population background near 4.6 per 10,000 endoscopies.

Can I drink clear liquids before my procedure?

Standard fasting allows clear liquids up to two hours before anesthesia for most patients, and a longer clear liquid diet may be recommended specifically for higher-risk GLP-1 users. Follow the exact instructions from your surgical team, since protocols vary by institution.

Does it matter which GLP-1 drug I take?

Yes. Weekly drugs like semaglutide, dulaglutide, and tirzepatide last for days and carry more lingering gastric-emptying effect, while daily drugs like liraglutide and oral semaglutide clear faster. Tell the team the exact drug and schedule so they can judge your risk accurately.

When can I take my GLP-1 again after surgery?

Usually once you are eating and drinking normally and your gut has settled, rather than while you are still nauseated. If you were increasing your dose before surgery, your prescriber may restart you at a lower step. Confirm the timing with the clinician who prescribes it.

I take a GLP-1 for diabetes, not weight. Does that change anything?

The aspiration reasoning is the same, but pausing the drug removes part of your blood sugar control, so a hold needs a glucose plan. Make sure whoever manages your diabetes and whoever manages your surgery are coordinating, and watch your numbers more closely around the procedure.

This article is for general information and is not medical advice. Perioperative GLP-1 management is individualized. Always follow the specific instructions of your surgeon, anesthesiologist, and prescriber, and do not start or stop any medication without consulting a qualified clinician.

Related: compare GLP-1 telehealth options.